NCT04840589: Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Therapeutic antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Patients with more than 5 lines of prior therapy; Patients with known active central nervous system (CNS) metastases and/or leptomeningeal disease; Patients with prior PD-1, PD-L1, or CTLA-4 inhibitor therapy

Comments are closed.

Up ↑